Top 50 Biotechnology VC Funds & Investors in Switzerland (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Zürcher Kantonal Bank
VC Fund
|
37 | Switzerland, Germany, Japan | Seed, Series A, Series B | Health Care, Biotechnology, Medical Device | $1.2M–$20M |
|
Foundation for Innovation and Technology (FIT)
VC Fund
|
34 | Switzerland, France, United States | Debt Financing, Grant, Seed | Health Care, Biotechnology, Artificial Intelligence | $13k–$1.1M |
|
Verve Ventures
VC Fund
|
19 | Switzerland, Germany, France | Series A, Seed, Series B | Health Care, Software, Biotechnology | $1.4M–$45M |
|
BioMedPartners
VC Fund
|
19 | Switzerland, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.9M–$75M |
|
VI Partners
VC Fund
|
14 | Switzerland, Germany, United States | Series A, Series B, Seed | Health Care, Biotechnology, Software | $1.3M–$41M |
|
M Ventures
VC Fund
|
13 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
EQT Life Sciences
VC Fund
|
12 | United States, The Netherlands, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $7.3M–$165M |
|
Eclosion SA
VC Fund
|
11 | Switzerland | Seed, Series C | Biotechnology, Pharmaceutical, Health Care | $1.6M–$28M |
|
Novartis Venture Fund
VC Fund
|
11 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$120M |
|
Sofinnova Partners
VC Fund
|
10 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6.6M–$109M |
|
Schroder Adveq
VC Fund
|
10 | Switzerland, United States, India | Series B, Series C, Series A | Biotechnology, Health Care, Therapeutics | $5.6M–$100M |
|
SICTIC
VC Fund
|
10 | Switzerland, Germany, Tanzania | Seed, Pre-Seed | Software, Artificial Intelligence, Information Technology | $302k–$3.4M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
10 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $909k–$39M |
|
Versant Ventures
VC Fund
|
9 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $5M–$108M |
|
Kinled Holding
VC Fund
|
9 | United Kingdom, United States, Switzerland | Seed, Series A | Biotechnology, Health Care, Software | $594k–$40M |
|
redalpine
VC Fund
|
9 | Germany, Switzerland, United Kingdom | Seed, Series A, Series B | Biotechnology, Health Care, Software | $1.6M–$125M |
|
Kickfund
VC Fund
|
9 | Switzerland, Germany | Seed, Pre-Seed, Convertible Note | Biotechnology, Health Care, Manufacturing | $110k–$5.7M |
|
Bernina BioInvest
VC Fund
|
9 | Switzerland | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $1.7M–$65M |
|
Lichtsteiner Foundation
VC Fund
|
8 | Switzerland | Seed, Series A | Biotechnology, Health Care, Medical | $1.6M–$6.8M |
|
Index Ventures
VC Fund
|
7 | United States, United Kingdom, France | Series A, Series B, Seed | Software, E-Commerce, Internet | $1.5M–$102M |
|
Novo Holdings
VC Fund
|
7 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.9M–$135M |
|
4FOX Ventures
VC Fund
|
7 | Switzerland, United States | Series A, Seed, Series B | Medical Device, Medical, Health Care | $2.1M–$69M |
|
GoBeyond
VC Fund
|
7 | Switzerland, Germany, United Kingdom | Seed, Series A | Information Technology, Medical, Software | $544k–$10M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
6 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
Swisscom Ventures
VC Fund
|
6 | Switzerland, United States, United Kingdom | Series B, Series A | Software, SaaS, Information Technology | $1.8M–$60M |
|
Privilège Ventures
VC Fund
|
5 | Switzerland, Italy, France | Seed, Pre-Seed, Series A | Health Care, Software, Wearables | $667k–$7M |
|
Pfizer Venture Investments
VC Fund
|
5 | United States, United Kingdom, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$120M |
|
Omega Funds
VC Fund
|
5 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Founderful
VC Fund
|
5 | Switzerland, United Kingdom, Canada | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $1.2M–$24M |
|
Pureos Bioventures
VC Fund
|
5 | France, Switzerland, United States | Series A, Series B, Series C | Biotechnology, Therapeutics, Medical | $6.6M–$125M |
|
Broadview Ventures
VC Fund
|
5 | United States, Switzerland, Canada | Series A, Seed, Series B | Health Care, Biotechnology, Medical Device | $1M–$45M |
|
b2venture
VC Fund
|
4 | Germany, Switzerland, United Kingdom | Series A, Seed, Series B | Software, Health Care, Information Technology | $1.3M–$52M |
|
Aargauische Kantonalbank
VC Fund
|
4 | Switzerland | Series B, Seed, Series A | Medical Device, Dental, Medical | $1.6M–$3.6M |
|
Inkef
VC Fund
|
4 | The Netherlands, United States, Germany | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $2.8M–$86M |
|
Neomed Management
VC Fund
|
4 | Switzerland, United States, Italy | Series B, Series C, Series A | Health Care, Biotechnology, Medical | $8.3M–$65M |
|
Aravis Ventures
VC Fund
|
4 | Switzerland, United States, Denmark | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $4.4M–$80M |
|
New Enterprise Associates
VC Fund
|
4 | United States, India, United Kingdom | Series A, Series B, Series C | Software, Health Care, Biotechnology | $5.8M–$110M |
|
Fongit Seed Invest
VC Fund
|
4 | Switzerland | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $1.2M–$3.7M |
|
Gilde Healthcare
VC Fund
|
4 | United States, The Netherlands, Germany | Series B, Series C, Series A | Health Care, Biotechnology, Medical | $9.5M–$135M |
|
OrbiMed
VC Fund
|
4 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $10M–$183M |
|
Polytech Ventures
VC Fund
|
4 | Switzerland, United States, Spain | Seed, Series A | Financial Services, FinTech, Software | $1M–$9.7M |
|
Endeavour Vision
VC Fund
|
4 | United States, Switzerland, France | Series C, Series B, Series A | Health Care, Medical, Biotechnology | $2.1M–$115M |
|
JFG Life Sciences Foundation
VC Fund
|
3 | Switzerland | Seed, Pre-Seed | Biotechnology, Medical, Biopharma | $5.2M–$13M |
|
BlueOcean Ventures
VC Fund
|
3 | Switzerland, India, France | Seed, Series A, Series B | Health Care, Medical, Personal Health | $1M–$20M |
|
Swisscanto Private Equity
VC Fund
|
3 | Switzerland, Denmark, Germany | Series B, Series C, Venture - Series Unknown | Health Care, Biotechnology, Manufacturing | $9.2M–$54M |
|
FAST — by GETTYLAB
VC Fund
|
3 | United States, United Kingdom, France | Pre-Seed, Seed | Software, Artificial Intelligence, Health Care | $125k–$7.6M |
|
Viva BioInnovator
VC Fund
|
3 | United States, China, Canada | Venture - Series Unknown, Seed, Series A | Biotechnology, Health Care, Medical | $2.3M–$20M |
|
Serpentine Ventures
VC Fund
|
3 | Switzerland, Germany, United States | Seed, Pre-Seed | Software, Information Technology, Automotive | $650k–$7M |
|
Wille Finance
VC Fund
|
3 | France, Germany, Switzerland | Series A, Seed | Health Care, Software, Biotechnology | $396k–$36M |
|
Inserm Transfert Initiative
VC Fund
|
3 | France, Switzerland, United States | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.1M–$60M |
| Access all 650 VC funds in Switzerland Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Switzerland, Germany, Japan
Investor stats
- Total investments: 200
- Round size: Seed $1.2M–$6M; Series A $2.3M–$13M; Series B $1.9M–$20M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Riverkin — Riverkin builds rugged, low-cost water sensor systems for rivers that measure turbidity and temperature in real time. Our platform turns field data into clear insights and decision making tools.
- QualySense — QualySense is a Swiss start-up company focused on innovative high-throughput grain, beans and seeds sorting technology. QualySense develops a high-speed multi-tons per hour sorting device, which will change how grains, beans and seeds are processed and valued worldwide by assessing the biochemical quality of grains one by one. The QualySensesorters will enable customers to separate grain batches into different biochemical quality classes and sell the corresponding premium products at higher average prices. Food processors will be able to considerably increase the production value, and produce higher quality products in a non-interrupted process.
- Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Artificial Intelligence
- Stage:Debt Financing, Grant, Seed
- Geography: Switzerland, France, United States
Investor stats
- Total investments: 204
- Round size: Seed $117k–$1.1M; Grant $13k–$125k; Debt Financing $100k–$566k
- Lead/follow: 93% lead, 7% follow
Portfolio highlights
- MyStones — MyStones - the athlete-centric platform redefining track and field. Daily progress into clear, shareable insights.
- Skilder Ai — skilder is the Agent Skills Management Platform to govern AI across Claude, ChatGPT and Copilot. Sovereign hosting, full governance, vendor-agnostic.
- Isospec Analytics — Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are unlocking the potential of glycomics and metabolomics in disease biomarker discovery and for the development of safer nutritional and pharmaceutical products.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 285
- Round size: Seed $1.4M–$11M; Series A $2.3M–$18M; Series B $4.2M–$45M
- Lead/follow: 13% lead, 87% follow
- Last fund: Likely still investing — raised $66M in 2022
Portfolio highlights
- Axelera AI — Axelera AI is a company that delivers purpose-built hardware and software platforms designed to accelerate artificial intelligence tasks, particularly in edge computing. The company's flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions.This platform has been recognized for its innovation, notably being named a CES® 2024 Innovation Awards Honoree.Incubated in 2019 by the emerging technologies leader Bitfury and joined by the leading nano-technology group imec in early 2020, Axelera AI launched as a new company in 2021. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AI has R&D offices in Belgium, Switzerland, and Italy. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies.
- Aylight — Aylight develops semiconductor laser and photonics platforms designed to improve optical connectivity in AI datacenters and related infrastructure. The company focuses on frequency modulated comb laser technology that generates multiple stable wavelengths from a single InP-based laser cavity. Its architecture produces an equidistant, RF-lockedwavelength grid that aligns with dense wavelength-division multiplexing requirements and reduces control complexity and power consumption. Aylight targets use cases in AI datacenter interconnects, quantum computing hardware, precision metrology, and communication equipment. Its products aim to integrate with terabit optical links and wavelength-division multiplexing systems while remaining compatible with existing fabrication processes.
- Atana Elements — Atana is a data-driven resource company that accelerates the exploration and development of flowing critical minerals.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 88
- Round size: Series A $5.3M–$31M; Series B $4.9M–$75M; Series C $5.8M–$47M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — raised $113M in 2018
Portfolio highlights
- T-CURX — T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges ...
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Vi Partners is a venture capital firm backing exceptional founders in healthcare and technology across Switzerland and Europe for over 25 years.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Seed
- Geography: Switzerland, Germany, United States
Investor stats
- Total investments: 112
- Round size: Seed $1.3M–$6.5M; Series A $3.7M–$23M; Series B $3.3M–$41M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $117M in 2020
Portfolio highlights
- Equippo.com — Used construction equipment marketplace. Easy and safe. Only inspected machines. Worldwide delivery. Money Back Guaranteed. Buy Now, Pay Later!
- Pay by Shopping (deal united) — paybyshopping.com Domain Name is available to Buy. Grab this great Domain from Daaz. Daaz has the lowest transaction fees in the industry. See our list of GTLD's,CCTLD's, New GTLD's,3N's, 6N's, 3L's, 6L's etc.
- Sonic Emotion — Sonic Emotion Absolute 3DTM sound technology provides an innovative unique solution for an immersive natural 3D sound reproduction by implementing audio products with sound field control from only 2, 3, 4 or 6+ channels using a single compact device (and an optional subwoofer internal or external).
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 174
- Round size: Seed $2.4M–$24M; Series A $5.6M–$50M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Cyllene Therapeutics — EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- ApoGen Biotechnologies — Explore fast payout casinos that deliver winnings instantly or under 24 hours. List of the best payout casinos to get same day winnings.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, The Netherlands, Switzerland
Investor stats
- Total investments: 184
- Round size: Series A $7.3M–$78M; Series B $12M–$110M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $266M in 2023
Portfolio highlights
- ActoGeniX — ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.
- Neurent Medical — Discover NEUROMARK, a minimally invasive solution for Chronic Rhinitis that targets the posterior nasal nerve to provide lasting symptom relief.
- Rotation Medical — Rotation Medical Inc. manufactures and markets a collagen scaffold for rotational cuff disease in Minnesota. The company was formerly known as Denali Medical Inc. and changed its name to Rotation Medical Inc. in March 2010. Rotation Medical was founded in 2009 and headquartered in Plymouth, Minnesota.
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Seed, Series C
- Geography: Switzerland
Investor stats
- Total investments: 16
- Round size: Seed $1.6M–$2.7M; Series C $20M–$28M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
- Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
- MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 219
- Round size: Series A $5.1M–$81M; Series B $11M–$120M; Series C $9M–$75M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Bionano Genomics — Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome.
- Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.
- Twentyeight-Seven Therapeutics — Maxslot88 merupakan link situs slot gacor gampang menang jackpot maxwin hari ini sebagai daftar apk slot88 terpercaya dengan server thailand resmi, memberikan pengalaman bermain slot online yang aman dan menghibur bagi semua klien.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 329
- Round size: Series A $6.6M–$70M; Series B $10M–$109M; Series C $12M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
- Comet Biorefining — Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosicglucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Series A
- Geography: Switzerland, United States, India
Investor stats
- Total investments: 36
- Round size: Series A $5.6M–$23M; Series B $11M–$73M; Series C $15M–$100M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — raised $113M in 2020
Portfolio highlights
- Bizongo — Bizongo is a Tech-Enabled B2B Platform for Packaging, Apparels & Other Customised Goods. We digitally transform vendor management & supply chain.
- Lenskart — Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able to do in India yet.The website has over 500 designs ofeye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery.Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision to name a few) and be it disposable, toric, colored, or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
- Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
SICTIC is the leading angel investor network in Switzerland with the largest Swiss seed-stage startup dealflow.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Switzerland, Germany, Tanzania
Investor stats
- Total investments: 289
- Round size: Seed $537k–$3.4M; Pre-Seed $302k–$2.7M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Agrinorm — Agrinorm is a Swiss deep tech company leveraging cutting edge machine learning techniques for the optimization of fruits and veg supply chains.
- hypt — hypt is a Swiss based SaaS marketing solution that empowers companies to digitalize word-of-mouth. By using our word-of-mouth manager companies are able to activate 40% of their customers to send out a personal recommendation to their peers increasing sales through word-of-mouth by 4 times. Our solution empowers our ICP customers in the finance andinsurance segments to strategically use and optimize the most authentic and cost effective advertising channel – word-of-mouth – and makes it an accessible asset of every marketing mix.
- Carewell — Carewell is influencing the way people work in healthcare by providing flexible digital solutions tailored to their specific needs.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 610
- Round size: Seed $909k–$7M; Series A $3.5M–$39M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- CorTec — Reliable products for active implantable device development. We realize your next project with you and offer individual solutions that meet your specific requirements for Medical Devices, especially in neurotechnology.
- Coinlend — Coinlend - The Lending-Bot for Bitfinex & Liquid Genearate interest from your Bitcoin and Altcoin investments!
- CenterPoint - Connective Software Engineering — CenterPoint was founded in 2000 and is based in Villach, Austria with an additional office in Warsaw, Poland. CenterPoint - Connective Software Engineering develops and markets process control and fault detection and classification software solutions. The company offers cause effect analysis, metrology assessment, and close loop and run to runcontrol services. It's focus are the semiconductors, electronics, and steel and alloy industries.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 296
- Round size: Series A $5M–$72M; Series B $10M–$107M; Series C $12M–$108M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Graphite Bio — Graphite Bio is a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases
- Dayra Therapeutics — Dayra Therapeutics manufactures peptide based medicines.
- Jecure Therapeutics — Jecure Therapeutics is focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis.
Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 139
- Round size: Seed $594k–$14M; Series A $1.7M–$40M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Esper — Esper is the first cloud-based platform to help governments proactively manage public policy with better data and transparency.
- Varda — Expanding the economic bounds of humankind with the world's first orbital manufacturing & reentry platform.
- TAG Therapeutics — TAG Therapeutics develops precision medicine approaches for telomere pathologies and aging-related diseases, such as Idiopathic Pulmonary Fibrosis and Short Telomere Syndromes
redalpine is a thesis-driven vc with deep expertise in software and science. since 2006. we believe in the power of big ideas and in empowering game changers. we don't just invest, we co-create a better tomorrow. together with you.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: Germany, Switzerland, United Kingdom
Investor stats
- Total investments: 197
- Round size: Seed $1.6M–$13M; Series A $3.2M–$31M; Series B $15M–$125M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $25M in 2013
Portfolio highlights
- microagi — Accelerating embodied AGI
- telli — The platform for AI phone calls. https://t.co/yOOUfNYMFe - used by 100+ enterprises - backed by @ycombinator & @cherryventures
- Proxima Fusion — We are a European fusion energy startup pursuing the clearest path to grid deployment.
Kickfund is a Venture Capital fund that systematically backs companies that successfully complete Venture Kick.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: Switzerland, Germany
Investor stats
- Total investments: 49
- Round size: Seed $1.1M–$5.7M; Pre-Seed $335k–$4M; Convertible Note $110k–$118k
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Immitra Bio — Developing scalable in-vivo genomic medicine for blood disorders
- Carewell — Carewell is influencing the way people work in healthcare by providing flexible digital solutions tailored to their specific needs.
- BLEEDnFIRE Therapeutics — BLEEDnFIRE Therapeutics: At BLEEDnFIRE Therapeutics, we are pioneering innovative siRNA-based therapies for hemophilia, Von Willebrand disease & other rare bleeding disorders (RBDs) by developing BnF-001. Our mission is to transform patient care and improve quand improve quality of life through targeted ...
Bernina BioInvest is an investment Firm.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 12
- Round size: Seed $1.7M–$20M; Series A $17M–$65M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Versameb — Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 11
- Round size: Seed $1.6M–$6.8M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Hemostod — Developing universal platelets and next-generation diagnostics
- DigeHealth — DigeHealth's approach to monitoring gut health using bowel noises and body measurements could provide some really valuable insights into digestive well-being.
- Allegria Therapeutics — Allegria Therapeutics operates as a biotech company.
Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.
Show more...Investment focus
- Industry: Software, E-Commerce, Internet
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 1339
- Round size: Seed $1.5M–$15M; Series A $5M–$38M; Series B $11M–$102M
- Lead/follow: 44% lead, 56% follow
- Last fund: May invest from a new fund soon — raised $117M in 2015
Portfolio highlights
- Anrok — Anrok automates sales tax compliance across your financial stack, so you can grow your SaaS business in any market.
- Pets Deli — PETS DELI is a leading D2C pet food brand in Germany with a clear focus on subscription based eCommerce, headquartered in Berlin. The company’s vision is to become the ultimate biggest and most customer centric D2C pet food brand in its core markets. PETS DELI’s unique business model is based on multiple diversified and recurring revenuestreams: The company markets its superior product offerings via online subscriptions, their online shop, offline flagship stores as well as selected partners in the most dominant retail chains.
- Acutus Medical — Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 370
- Round size: Series A $9.9M–$133M; Series B $12M–$135M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Tarveda Therapeutics — Developing Pentarins to make a difference in the treatment of patients with solid tumor malignancies
- Tarsa Therapeutics — Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
4FO Ventures
Show more...Investment focus
- Industry: Medical Device, Medical, Health Care
- Stage:Series A, Seed, Series B
- Geography: Switzerland, United States
Investor stats
- Total investments: 23
- Round size: Seed $2.1M–$3.6M; Series A $2.1M–$11M; Series B $5.5M–$69M
- Lead/follow: 52% lead, 48% follow
Portfolio highlights
- Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
- Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
- Neo Medical — Neo aims at transforming the current approach to spinal surgery by providing a unique answer to the worldwide strive for healthcare cost optimization through efficient, versatile and high quality systems.
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more...Investment focus
- Industry: Information Technology, Medical, Software
- Stage:Seed, Series A
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 164
- Round size: Seed $544k–$5M; Series A $1.2M–$10M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Stylect — Stylect is a mobile app to to help women discover their perfect shoe. They aggregate products from multiple websites and based on users' preferences (that they gather through a hot-or-not interface), they recommend better products. Their users are able to keep track of and buy the products they like and receive notifications whenever a productthey love goes on sale. Finally, They use geolocation to let their users know when a shoe is selling in a store nearby.
- Prestodiag — Prestodiag develops, manufactures and sells innovative solutions for rapid detection of bacteria. Their analytical solutions are based on an innovative optics technology called Surface Plasmon Resonance imaging and allow detection and identification of pathogenic bacteria such as Salmonella, Listeria or E.coli. They provide users with a result injust a few hours instead of 1 to several days. Their market is primarily the food safety sector, and also on medical and environmental applications.
- Arktis Radiation Detectors — Arktis develops and manufactures next generation systems that detect and categorize radiological and nuclear materials to enhance security and operations.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 104
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
- smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
- Rinri Therapeutics — Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Series B, Series A
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 151
- Round size: Series A $1.8M–$23M; Series B $4.1M–$60M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- Apono — Apono makes permission management to applications, infrastructure, and data repositories simple, secure and compliant.
- CDDS — CDDS is a defense technology firm producing AI-powered autonomous interceptor drones for countering unmanned aerial systems.
- Aylight — Aylight develops semiconductor laser and photonics platforms designed to improve optical connectivity in AI datacenters and related infrastructure. The company focuses on frequency modulated comb laser technology that generates multiple stable wavelengths from a single InP-based laser cavity. Its architecture produces an equidistant, RF-lockedwavelength grid that aligns with dense wavelength-division multiplexing requirements and reduces control complexity and power consumption. Aylight targets use cases in AI datacenter interconnects, quantum computing hardware, precision metrology, and communication equipment. Its products aim to integrate with terabit optical links and wavelength-division multiplexing systems while remaining compatible with existing fabrication processes.
Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary over five decades of combined investment experience Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary Authentic, dedicated, disciplined, and goal-oriented, our team drives meaningful and lasting success About Team
Show more...Investment focus
- Industry: Health Care, Software, Wearables
- Stage:Seed, Pre-Seed, Series A
- Geography: Switzerland, Italy, France
Investor stats
- Total investments: 24
- Round size: Seed $1.2M–$5.9M; Pre-Seed $667k–$1.6M; Series A $4.1M–$7M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- Xsensio — Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developedat the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.
- ENANTIOS — ENANTIOS specializes in creating benchtop analytical instruments that provide industries, research institutions, and academic facilities.
- Develop Players — Supporto clinico per ADHD e DSA online. Aiutiamo adulti, bambini e ragazzi con screening, potenziamento e percorsi psicologici personalizzati.
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 179
- Round size: Series A $10M–$100M; Series B $20M–$120M; Series C $15M–$102M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $600M in 2018
Portfolio highlights
- Ixchelsis — Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose studyin healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health therapeutic area.
- Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
- Flexion Therapeutics — Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 161
- Round size: Series A $16M–$187M; Series B $37M–$162M; Series C $14M–$208M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Attenua — 100% satisfaction guaranteed. Hassle-free shopping. We help you find the right domain name.
- Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
- Chord Therapeutics — Chord Therapeutics is a clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. We are advancing our lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG).
Founderful operates as a venture capital firm and a Switzerland’s leading pre-seed fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Switzerland, United Kingdom, Canada
Investor stats
- Total investments: 105
- Round size: Seed $1.5M–$14M; Pre-Seed $1.2M–$4.3M; Series A $3.4M–$24M
- Lead/follow: 56% lead, 44% follow
- Last fund: Likely still investing — raised $85M in 2024
Portfolio highlights
- AVIAN — AVIAN helps industrial teams prevent fires and downtime with continuous thermal monitoring, abnormal-heat detection, alerts, and response workflows.
- Stellar Alpina — Stellar Alpina develops modular lunar landers and the RDRE propulsion modules that power them, combining rapid hardware iteration with a scalable platform approach for reliable missions from Earth orbit to the Moon.
- Exclaim Robotics — Autonomous mobile robots for the AI data center.
Venture capital for companies developing innovative therapeutics.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Medical
- Stage:Series A, Series B, Series C
- Geography: France, Switzerland, United States
Investor stats
- Total investments: 35
- Round size: Series A $15M–$123M; Series B $6.6M–$100M; Series C $22M–$125M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — raised $205M in 2020
Portfolio highlights
- Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
- Tavo Biotherapeutics — Tavo Biotherapeutics is a biotech company that develops injection therapies for eye diseases.
- PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Seed, Series B
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 82
- Round size: Seed $1M–$18M; Series A $1M–$30M; Series B $7M–$45M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Adient Medical — Medical Devices that Automatically Vanish - Adient Medical is leading the development of an absorbable vascular filter for the prevention of pulmonary embolism.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Viridian Therapeutics (Formerly MiRagen Therapeutics) — Committed to developing potential best-in-class medicines for people affected by Thyroid Eye Disease and other autoimmune and rare diseases.
B2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed, Series B
- Geography: Germany, Switzerland, United Kingdom
Investor stats
- Total investments: 244
- Round size: Seed $1.3M–$9M; Series A $4M–$24M; Series B $8.3M–$52M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $135M in 2021
Portfolio highlights
- Everlab — The preventative health service of the future. Detect disease early, improve wellbeing, and optimise performance.
- Flyboard — Human-level AI voice agents at a fraction of the cost. Transform your customer engagement with intelligent automation.
- Kiin Bio — Drug discovery is a system problem, where every inefficiency amplifies the next. We have the solution.
Aargauische Kantonalbank (AKB) is a classical universal bank for private and corporate clients and institutional investors. They offer comprehensive services in all areas of banking. Their strengths include the needs-based, personalized and comprehensive advice and a comprehensive and competent care. The AKB has 31 offices in the canton of Aargauand the adjacent area Solothurn Olten-Gösgen-Gäu. Their company has about 790 employees and about 79 students. They serve approximately 230,000 customers. The AKB has been awarded by the rating agency Standard & Poor's AA + rating.
Show more...Investment focus
- Industry: Medical Device, Dental, Medical
- Stage:Series B, Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 12
- Round size: Seed $1.7M–$3.6M; Series B $1.6M–$2.3M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Aliunid — Aliunid is a cleantech startup that records, optimizes, and controls energy flows using real-time data.
- Mesh — MESH is automating rebar fabrication and construction processes using robotics and software. Our mission is to bring modern robotics to rebar industry.
- Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: The Netherlands, United States, Germany
Investor stats
- Total investments: 89
- Round size: Seed $2.8M–$24M; Series A $3.2M–$42M; Series B $8.2M–$86M
- Lead/follow: 48% lead, 52% follow
- Last fund: May invest from a new fund soon — raised $585M in 2016
Portfolio highlights
- Silverflow — Silverflow offers global payment technology to power financial institutions.
- Provable Markets — A comprehensive suite of trading & trade management solutions for the front, middle, and back office
- Quantum Motion — Quantum Motion delivers scalable silicon-based quantum computing using standard semiconductor manufacturing technology.
NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series C, Series A
- Geography: Switzerland, United States, Italy
Investor stats
- Total investments: 41
- Round size: Series A $8.3M–$37M; Series B $20M–$65M; Series C $10M–$44M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
- Oxular — Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
- JenaValve Technology — Redefining what it means to treat patients with severe aortic regurgitation.
Aravis is the first independent Swiss on-shore private equity house, an established investor in the renewable energy and life science spaces. We are a "hands-on" investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30leading investors including corporates, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of several renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in the Swiss fund industry have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Switzerland, United States, Denmark
Investor stats
- Total investments: 19
- Round size: Series A $4.4M–$80M; Series B $6.8M–$33M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Bird Rock Bio — We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.
- Synaffix BV — Synaffix BV is a clinical-stage, Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) thatenables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035.Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products for their own pipelines.Disclosed partnerships to date include those with ADC Therapeutics and Mersana Therapeutics
- Hedera-22 — Hedera-22 expanded its scope to include the identification of natural products through the use of in-house bio-informatic prediction technologies.
Foundational partners to ambitious founders at every stage of company-building.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1679
- Round size: Series A $5.8M–$60M; Series B $10M–$85M; Series C $15M–$110M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $2.8B in 2022
Portfolio highlights
- NeuroPace — The NeuroPace RNS System is the only FDA-approved epilepsy device that delivers personalized treatment by responding to abnormal brain activity and provides EEG data that can help improve patient care.
- Packeteer — Packeteer is a global leader in WAN Application Delivery and WAN Optimization. The company offers an integrated family of appliances and software products. Packeteer is a provider of network software products that enhance mission-critical application performance over enterprise WANs and the Internet. These application-adaptive bandwidth managementsolutions give businesses and service providers per-application control of bandwidth at congested WAN access links.
- Alteon Websystems — Alteon Websystems is a computer network hardware company that provides internet infrastructure solutions enabling e-businesses to meet their increasing demands. The company’s portfolio of web data center products includes switches, server adapters, and software that are optimized to meet the specific challenges of managing web application trafficand provide high performance network infrastructure solutions.Alteo Websystems was founded in 1996 and is headquartered in San Jose, California.
Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 9
- Round size: Seed $1.2M–$1.4M; Series A $2.3M–$3.7M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, The Netherlands, Germany
Investor stats
- Total investments: 131
- Round size: Series A $9.5M–$63M; Series B $15M–$135M; Series C $21M–$75M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $786M in 2023
Portfolio highlights
- Big Health — Our mission is to help millions back to good mental health. Our digital therapeutics are safe and effective non-drug alternatives for mental health.
- GT Medical Technologies — GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors.
- Endovascular Engineering — Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 653
- Round size: Series A $10M–$150M; Series B $24M–$150M; Series C $18M–$183M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- CardiAQ Valve Technologies — CardiAQ Valve Technologies (CVT), a privately held company, is developing innovative approaches to heart valve replacement and is initially focused on transcatheter mitral valve implantation (TMVI).
- Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
- Acceleron Pharma — At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world
Show more...Investment focus
- Industry: Financial Services, FinTech, Software
- Stage:Seed, Series A
- Geography: Switzerland, United States, Spain
Investor stats
- Total investments: 50
- Round size: Seed $1M–$5M; Series A $2.3M–$9.7M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $40M in 2016
Portfolio highlights
- Relai — All you need to get started is to download our award winning Relai app, complete a simple verification and start buying with as little as 50 CHF/EUR.
- Hemostod — Developing universal platelets and next-generation diagnostics
- Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
Endeavour Vision is an investment advisory firm focused on transformative healthcare technologies.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series C, Series B, Series A
- Geography: United States, Switzerland, France
Investor stats
- Total investments: 70
- Round size: Series A $2.1M–$30M; Series B $7M–$45M; Series C $12M–$115M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $375M in 2021
Portfolio highlights
- Nalu Medical — Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
- Venture Med Group — Create a dynamic website for your electrical services with Avada & WordPress. Showcase your expertise, services, and attract clients with engaging designs.
- Kestra Medical Technologies, Inc. — Kestra Medical Technologies is a wearable medical device and digital healthcare company that protects patients with diagnostic and therapeutic technologies that are intuitive, and mobile. They provide intuitive medical technologies to protect and support at-risk patients.
JFG Life Sciences Foundation is a non-profit foundation.
Show more...Investment focus
- Industry: Biotechnology, Medical, Biopharma
- Stage:Seed, Pre-Seed
- Geography: Switzerland
Investor stats
- Total investments: 3
- Round size: Seed $5.2M–$13M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- TECregen — TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses.
- Invasight — Invasight is a clinical biotech company that focused on revolutionizing cell invasion research. The company was founded in 2019 and is headquartered in Zurich, Switzerland.
- NXI Therapeutics — NXI Therapeutics - Creating Tomorrow's Immunotherapies | The beginning of a new era of specificity and safety in the immunosuppressive therapy market
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
Show more...Investment focus
- Industry: Health Care, Medical, Personal Health
- Stage:Seed, Series A, Series B
- Geography: Switzerland, India, France
Investor stats
- Total investments: 17
- Round size: Seed $1M–$3.1M; Series A $2.3M–$20M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Augurix — Augurix was born out of the real-life experiences of living with Celiac Disease. In 2004, Cecile – a pediatrician with an MD and PhD in immunology – noticed her 18-month old son Simon exhibiting symptoms of the disease. As a professional and having been diagnosed herself some thirty years earlier, she was able to spot the early warning signs. ButCecile was also acutely aware that despite affecting almost 1 in 100 people, Celiac Disease was difficult to diagnose.Cecile and her husband Thierry became determined to find a way to change this, giving parents and their children the best chance of an accurate diagnosis and the ability to live their lives free of the often debilitating symptoms. Using Swiss medical expertise Augurix was founded in 2007, with a mission to provide primary care doctors with an easy-to-use, affordable tool, to lower the hurdle of diagnostics.In 2010 Simtomax® was launched – a rapid screening test for the early determination of Celiac Disease at the point-of-care – finally bringing Cecile’s vision to life. Today, Augurix is pursuing its vision by enlarging its diagnostics offer to other gastrointestinal diseases.
- official.fm — Music to discover and share.
- Rheon Medical — Rheon Medical manufactures eyeWatch, a drainage device for the treatment of glaucoma. It also offers control unit, an instrument that measures and adjusts the eyeWatch's functional position. Rheon Medical began operation in 2010. Its headquarters is in Lausanne in Switzerland.
We invest in growth companies in the "late-stage venture/growth capital" phase, focussed on the technology and healthtech sectors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series B, Series C, Venture - Series Unknown
- Geography: Switzerland, Denmark, Germany
Investor stats
- Total investments: 35
- Round size: Series B $9.2M–$52M; Series C $22M–$54M; Venture - Series Unknown $20M–$47M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — raised $204M in 2018
Portfolio highlights
- MedTrace Pharma — MedTrace is developing a solution that will help healthcare providers diagnose patients more accurately and quickly.
- ANYbotics — ANYbotics provides autonomous legged robots for industrial applications to provide high availability and reliability in automated routine inspections.
- Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
Backing engineers building awe, wonder, speed.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Pre-Seed, Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 108
- Round size: Seed $500k–$7.6M; Pre-Seed $125k–$2.3M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Modelwise — Automated functional safety analysis via drag & drop. Seamless Integration. Faster Analyses. Zero Defects. More Savings.
- Fluent Metal — Fluent Metal is a company that makes metal 3D printing economical, efficient, and safe.
- Integrated Reasoning — Integrated Reasoning builds computer hardware to efficiently solve optimization problems. We're making it faster and cheaper to solve problems like scheduling airline pilots or packing boxes into trucks.
Viva BioInnovator (VBI) is the specialized investment and incubation arm of Viva Biotech Holdings. We focus on the initial creation and development of biotech startups across all indications and drug types. During the early stages of drug discovery, we can nurture and accelerate a startup's growth from idea to clinical program. VBI'sunique investment and incubation model started out of necessity in 2014. Our roots are in drug discovery services, where we operate world-leading and proprietary drug discovery platforms. While serving big pharma customers from around the globe, we came to realize the huge demand from many entrepreneurs who have great ideas but cannot receive funding to advance their plan due to lack of data. We saw the value in many of these innovative ideas and provided our CRO drug discovery services, operational support, and monetary backing to help these creative scientists embark on the "0 to 1" transformation. This spark launched our "equity for service (EFS)" investment and incubation model. VBI is based in Shanghai, with an office in Boston and personnel in California. As of early 2019, VBI has invested in over 30 companies out of the hundreds of proposals submitted for review and we plan to invest at a rapid pace in the years to come. The majority of our current portfolio companies are US based, but we are open to proposals globally and are excited to see new ideas that fit our investment strategy. If you would like to learn more about us, please visit: www.vivabioinnovator.com Or send an email to innovation@vivabiotech.com If you would like to learn more about our parent company, Viva Biotech, please visit: www.vivabiotech.com
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Venture - Series Unknown, Seed, Series A
- Geography: United States, China, Canada
Investor stats
- Total investments: 56
- Round size: Seed $2.3M–$20M; Series A $3M–$20M; Venture - Series Unknown $3.5M–$8.6M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- Kainova Therapeutics — Domain Therapeutics is a biopharmaceutical company focused on GPCR in immuno-oncology. Discover more than you think on our innovative cancer treatments tackling GPCR mediated-immunosuppression
- Vincere Biosciences — Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD).
- Proviva Therapeutics, Inc — Prodrug design platform for cytokines and other fusion proteins
Serpentine Ventures (SERV) is the investment arm of the Swiss startup group. Serpentine refers to the meandering roads found across the Swiss Mountains. Unreachable mountain peaks become accessible by following the serpentine path.
Show more...Investment focus
- Industry: Software, Information Technology, Automotive
- Stage:Seed, Pre-Seed
- Geography: Switzerland, Germany, United States
Investor stats
- Total investments: 78
- Round size: Seed $1.2M–$7M; Pre-Seed $650k–$1.7M
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- Apaleo — Transform your hospitality business with an open platform. Easily connect 3rd party applications to build a best-in-class tech stack for your hotel
- Evulpo — Creating Futures - For students from Year 3 to Year 13. Exactly according to the national curriculum. Learn always and everywhere with evulpo.
- Isochronic — Isochronic manufactures industrial robotic products for pick and place applications by transporting multiple parts simultaneously.
An international, Swiss-based family office, focusing on private equity (venture & buy-out), real estate and listed assets.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed
- Geography: France, Germany, Switzerland
Investor stats
- Total investments: 37
- Round size: Seed $396k–$5.2M; Series A $6M–$36M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- Edflex — Edflex est une solution SaaS qui connecte les entreprises avec les meilleurs contenus de formation (MOOC, vidéos, podcasts, articles…).
- Newronika — Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.
- Happydemics — Measure and benchmark Brand lift across TV, DOOH, display, audio & more. Get proven insights to optimize every ad channel with Happydemics.
Inserm Transfert Initiative is a seed stage life science vehicle currently managing about €4.2M for the financing of new biotech companies. Inserm Transfert Initiative is the new investment vehicle of INSERM in France.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: France, Switzerland, United States
Investor stats
- Total investments: 22
- Round size: Seed $2.7M–$3.6M; Series A $1.1M–$35M; Series B $2.2M–$60M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Eyevensys — Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
- VectivBio — Explore Ironwood Pharmaceuticals' commitment to GI health with innovative therapies, patient-focused research, and a vision to improve digestive disease treatment.
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
Biotechnology VC funding in Switzerland at a glance
Stats across 821 deals from 650 investors.
Access all 650 VC funds in Switzerland Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology VC Funds in Switzerland investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 650 VC funds investing in Switzerland Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!